Goldman Sachs lowered estimates and its price target on King Pharmaceuticals, Inc. (NYSE: KG) from $10.50 to $9.50 following Q1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE